Optiva Inc

VEGF-A therapy has transformed nAMD treatment, yet real-world outcomes often fall short of clinical trial results. New treatments aim to enhance visual gains and durability, with sozinibercept showing promise in phase 2b trials for superior visual outcomes when combined with standard care.

Percheron's Duchenne muscular dystrophy trial failed, leading to a significant drop in share value. Opthea's shares are seen as undervalued, with potential for growth pending phase III trial results. Neurizon seeks FDA approval for a motor neurone disease trial. Prescient appoints a new CEO with extensive industry experience.

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

The article discusses the importance of enabling JavaScript to run web applications.

The U.S. House passed the BIOSECURE Act, banning U.S. biopharma companies from working with Chinese contractors due to national security concerns. This reflects shifting global biotech dominance, with immediate supply chain challenges and long-term implications. China’s biotech leadership, built over decades, contrasts with the West’s slow prioritization. The Act may encourage the U.S. and Europe to bring resources home, but short-term consequences for manufacturing, clinical trials, and IP are significant. A comprehensive “BIOBUILD” strategy is needed to maintain biotech leadership.

Leon Serry AM, known as the father of Australian biotech, founded Circadian (now Opthea Ltd) and pioneered the industry, overcoming scepticism and funding crises. He was a notable investor, philanthropist, and mentor, supporting early-stage biotechs and contributing to the commercialization of biomedical science. Serry was awarded a Member of the Order of Australia in 2017 for his significant service.

JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.